Adalimumab-associated multiple sclerosis.
Bensouda-Grimaldi
Lamiae
L
Mulleman
Denis
D
Valat
Jean-Pierre
JP
Autret-Leca
Elisabeth
E
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000175:diagnosis; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007142:Immunoglobulin gamma-Chains / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis; D009902:Optic Neuritis / Q000139:chemically induced / Q000175:diagnosis; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007142:Immunoglobulin gamma-Chains; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C099374:Ro 45-2081; D000068879:Adalimumab; D000068800:Etanercept